Skip to main content
Premium Trial:

Request an Annual Quote

Invitae: Roxi Wen, Katherine Stueland

Roxi Wen has been appointed as CFO of Invitae, effective June 21. She will replace Shelly Guyer, who will focus on the company's environment, social, and governance efforts. Wen joins Invitae from Mozilla, where she has been CFO. Prior to that, she was CFO at Elo Touch Solutions, and before that, VP of finance at FleetPride. Previously, she was CFO at General Electric Critical Power. Wen holds a bachelor of economics from Xiamen University and an MBA from the University of Minnesota.

Katherine Stueland will step down as chief commercial officer of Invitae, effective June 18, to become CEO at another company.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.